Results 161 to 170 of about 7,748 (215)

Immunotoxins

Biomedicine & Pharmacotherapy, 1989
openaire   +1 more source

Developing a 3D Model Culture of an EBV+/CD30+ B-Anaplastic Large Cell Lymphoma Cell Line to Assay Brentuximab Vedotin Treatment. [PDF]

Antibodies (Basel)
Giannoni P, Pietra G, Izzo O, Fugazza G, Benelli R, Poggi A, Krampera M, Utzeri C, Marchese M, Musso M, Visconti P, de Totero D.   +11 more
europepmc   +1 more source

GPC2 provides prognostic value in pan-pediatric cancers and is associated with MYCN amplification in neuroblastoma: bioinformatics analysis and validation. [PDF]

BMC Cancer
Xu Y, Zhou Z, Dong Y, Wang G, Zheng L, Lu X, Li S, Zhang M, Gong J, Yang J.   +9 more
europepmc   +1 more source

Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches. [PDF]

Antibodies (Basel)
Godugu D, Gattu K, Suri P, Daartey AB, Jadhav K, Rojekar S.   +5 more
europepmc   +1 more source

Enhanced Antitumor Efficacy of a Combination of Immunotoxin and Photosensitizer Under Illumination in Xenograft Mice. [PDF]

Biomedicines
Hamakubo S, Komatsu N, Kosai A, Kuroda M, Sawada M, Shimizu R, Ohashi R, Suenaga H, Hamakubo T, Abe T.   +9 more
europepmc   +1 more source

Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. [PDF]

Ther Adv Med Oncol
Izzo D, Ascione L, Guidi L, Marsicano RM, Koukoutzeli C, Trapani D, Curigliano G.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Immunotoxins

Cell, 1986
Ira Pastan
exaly   +3 more sources

Immunotoxins and nanobody-based immunotoxins: review and update

Journal of Drug Targeting, 2021
Immunotoxins (ITs) are protein-based drugs that compose of targeting and cytotoxic moieties. After binding the IT to the specific cell-surface antigen, the IT internalises into the target cell and kills it. Targeting and cytotoxic moieties usually include monoclonal antibodies and protein toxins with bacterial or plant origin, respectively.
Mohammad Reza Khirehgesh, Jafar Sharifi, Fatemeh Safari, Bahman Akbari   +3 more
openaire   +2 more sources

Immunotoxins: An Update

Annual Review of Immunology, 1996
The use of immunotoxins (ITs) in the therapy of cancer, graft-vs-host disease (GvHD), autoimmune diseases, and AIDS has been ongoing for the past two decades. ITs contain a targeting moiety for delivery and a toxic moiety for cytotoxicity. Theoretically, one molecule of a toxin, routed to the appropriate cellular compartment, will be lethal to a cell ...
G R, Thrush, L R, Lark, B C, Clinchy, E S, Vitetta   +3 more
openaire   +2 more sources

Neurotoxicity of immunotoxins

Molecular and chemical neuropathology, 1994
Immunotoxins are being tested for the therapy of systemic cancer and brain tumors. Neurotoxicity has been dose limiting for several of these antibody conjugates given systemically. We review the animal and clinical data related to the neurotoxicity of immunotoxins in attempt to understand the molecular basis for the unexpected neural involvement and to
O, Ilercil, D W, Laske, S, Walbridge, K, Muaszko, E H, Oldfield, R J, Youle   +5 more
openaire   +2 more sources